AZD6234
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel
AstraZeneca · Phase 1 · Active, not recruiting · Enrollment 100
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP) | n/r | n/r | n/r | n/r | n/r |
| Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP | n/r | n/r | n/r | n/r | n/r |
| Cohort-3: AZD9550 + EE/LEVO + APAP | n/r | n/r | n/r | n/r | n/r |
| Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.